How long does it take for ibrutinib/ibrutinib treatment to show effects?

Ibrutinib/Ibrutinib, as an innovative drug, has demonstrated significant therapeutic effects in many patients. Based on clinical data, significant clinical responses can be observed in some patients within three to six months of starting treatment. It is worth mentioning that the average duration of ibrutinib therapy in clinical trials reached approximately 41 months, ranging from 2 months to 51 months. For those patients who stopped taking ibrutinib for various reasons, their average survival after stopping the drug was 8 months.

The recommended starting dose of ibrutinib varies for patients with different conditions and age groups. For adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and Waldenstrom's macroglobulinemia (WM), the recommended starting dose is 420 mg daily. For patients with chronic graft-versus-host disease, the dose is adjusted according to age: adults and children 12 years and older have a daily dose of 420 mg, while children 1 to less than 12 years have a daily dose of 240 mg/m2 based on body surface area, but not to exceed 420 mg. If a patient experiences toxicity during treatment, the doctor may consider reducing the dose.

Given ibrutinib's important role in treating certain types of leukemia and solid tumors, most patients continue taking the drug indefinitely. This is because symptoms tend to return within a relatively short period of time once treatment is stopped, especially in patients who have not been taking ibrutinib for a long time or who have tried multiple other treatments. Therefore, continued administration of ibrutinib becomes a key strategy to ensure treatment efficacy and prolong cancer progression-free survival.